A Phase 1b/2 Study of Docetaxel and Prednisone, with or without ISIS 183750 (an eIF4E Inhibitor), inPatients with Castrate-Resistant Prostate Cancer
- Registry ID
- EUCTR2010-022239-12
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE2
- Sponsor
- Isis Pharmaceuticals, Inc.
- Start date
- 2011-05-05
- Completion date
- 2013-11-15
- Last update
- 2026-08-16
Conditions
- Metastatic castrate-resistant prostate cancer
Summary
In Part 1, the primary objective is to examine the safety and tolerability of ISIS 183750 in combination with docetaxel and prednisone in order to determine the ISIS 183750 dose for evaluation in Part 2. In Part 2, the primary objective is to estimate the progression-free survival in patients treated with ISIS 183750 in combination with docetaxel and prednisone.
Locations
View on source registry